Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $43.8 million.

  • Veracyte's Accumulated Expenses rose 10.26% to $48.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 10.26%. This contributed to the annual value of $43.8 million for FY2024, which is 14.05% up from last year.
  • Veracyte's Accumulated Expenses amounted to $43.8 million in FY2024, which was up 14.05% from $38.4 million recorded in FY2023.
  • Over the past 5 years, Veracyte's Accumulated Expenses peaked at $43.8 million during FY2024, and registered a low of $11.7 million during FY2020.
  • For the 3-year period, Veracyte's Accumulated Expenses averaged around $40.0 million, with its median value being $38.4 million (2023).
  • As far as peak fluctuations go, Veracyte's Accumulated Expenses declined by 14.77% in 2020, and later surged by 237.25% in 2021.
  • Veracyte's Accumulated Expenses (Yearly) stood at $11.7 million in 2020, then skyrocketed by 237.25% to $39.5 million in 2021, then fell by 4.31% to $37.8 million in 2022, then increased by 1.73% to $38.4 million in 2023, then grew by 14.05% to $43.8 million in 2024.